Sangui Biotech International, Inc. (SGBI)
ValueMarkers Composite Index
DCF data not available
Sangui Biotech International, Inc. (SGBI) — VMCI valuation read
The headline on Sangui Biotech International, Inc. (SGBI) is a 50/100 VMCI score, set against a Healthcare sector median of 50. That 0-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.
SGBI insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.
**Investor frame.** SGBI trades at 21.0x earnings, 17% above the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of -2.1x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on SGBI.
SGBI fell 3.2% over the trailing 7 days, with a -21.1% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.